The evolution of malignant and reactive γδ + T cell clones in a relapse T-ALL case after allogeneic stem cell transplantation

Table 1 Clinical therapy details for the patient with relapse T-ALL

Therapy date	Therapy	Response	Blast cells (%) post-treatment	CSF	Intrathecal chemotherapy
Therapy date	Therapy	Response	BM / PB	CSF	Intrathecal chemotherapy
18.11-01.12.2009	CTX, VCR, ADM, DXM	PR	11 / 3	-	MTX + DXM
18.12-22.12.2009	MTX, Ara-c , DXM	NR	37 / 3
25.01-30.01.2010	CTX, Ara-c, TPT	NR	47 / 1	-	Ara-c + DXM
05.03.2010	Allo-HSCT (conditioning regimen: Flu, BU/CY)	CR	1 / 0	-	MTX + DXM
13.04.2010	CsA, MP	GVHD (Grade II)	0.5 / 0
13.05.2010	CsA, MP	GVHD under control	1.5 / 0	-	MTX + DXM
12.08.2010- 07.01.2011	Radiotherapy	CNSL cured	0 / 0	+	(Ara-c + MTX + DXM) x 8 times
26.04-21.05.2012	VDS, NVT, L-ASPDXM	Relapse, CR	3 / 0	-	MTX + DXM (03.05 2012) Ara-c + DXM (25.05.2012)
08.06-06.07.2012	VCR, NVT, L-ASP, DXM, CTX	CR	1 / 0	-

Notes: ADM adramycin, Ara-c cytarabine, BM bone marrow, BU busulfan, CNSL central nervous system leukemia, CsA cyclosporin, CSF cerebrospinal fluid,CTX cyclophosphamide, CR complete remission, CY cyclophosphamide, DXM dexamethasone, Flu fludarabine, L-ASP l-asparaginase, MP methylprednisolone,MTX Methotrexate, NR minor remission, NVT mitoxantrone, PR partial remission, PB peripheral blood, TPT Topotecan, VCR vincristine, VDS Vindesine.

ISSN: 1476-4598